Analysts Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Price Target at $87.33

by · The Markets Daily

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report) have received a consensus recommendation of “Hold” from the eight research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $87.3333.

Several research analysts recently commented on PBH shares. Oppenheimer dropped their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, October 21st. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Jefferies Financial Group dropped their price target on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research report on Monday, October 27th. Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Thursday, September 4th. Finally, Wall Street Zen lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th.

Get Our Latest Analysis on PBH

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC boosted its position in shares of Prestige Consumer Healthcare by 4.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after buying an additional 70,376 shares during the period. Kayne Anderson Rudnick Investment Management LLC boosted its position in shares of Prestige Consumer Healthcare by 45.3% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock valued at $135,903,000 after buying an additional 493,199 shares during the period. Geode Capital Management LLC boosted its position in shares of Prestige Consumer Healthcare by 0.7% during the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock valued at $112,843,000 after buying an additional 9,455 shares during the period. Invesco Ltd. boosted its position in shares of Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock valued at $113,635,000 after buying an additional 261,537 shares during the period. Finally, Congress Asset Management Co. raised its stake in shares of Prestige Consumer Healthcare by 1.8% during the second quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company’s stock valued at $80,616,000 after acquiring an additional 18,015 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Down 1.2%

PBH opened at $59.78 on Thursday. The firm has a market cap of $2.94 billion, a P/E ratio of 14.03, a P/E/G ratio of 1.93 and a beta of 0.41. Prestige Consumer Healthcare has a 12 month low of $59.51 and a 12 month high of $90.04. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. The stock has a 50-day moving average of $63.26 and a 200 day moving average of $73.45.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.06). The company had revenue of $249.53 million during the quarter, compared to analysts’ expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The company’s revenue was down 6.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.90 EPS. As a group, research analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Recommended Stories